CERU Cerulean Pharma Inc.

-0.0115  -3%
Previous Close 0.41
Open 0.40
Price To book 1.54
Market Cap 11.56M
Shares 29,021,000
Volume 462,134
Short Ratio 0.38
Av. Daily Volume 3,284,960

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a portion of Phase 1/2a trial commenced dosing June 2016. Initial data due in 2017.
Solid tumours - cancer
Phase 1/2 trial commenced dosing May 2016. Top-line data due 2017.
CRLX101, in combination with LYNPARZA
Solid tumors - cancer
Further data due in 2017.
CRLX101 and paclitaxel
Platinum-resistant ovarian cancer
Phase 2 data released August 2016 failed to meet primary endpoint
CRLX101 and Avastin - RCC Trial
3rd and 4th line Relapsed Renal Cell Carcinoma cancer

Latest News

  1. Cerulean and Daré Announce Awards for Daré CEO
  2. As Cerulean Pharma winds down, executives get a parting gift: bonuses
  3. Cerulean and Daré to Host Conference Call on Proposed Transaction on March 23
  4. Waltham's Cerulean Pharma to cut staff, merge with San Diego biotech
  5. Cerulean Pharma and Daré Bioscience Enter into Stock Purchase Agreement
  6. Stick to Small, Fast Trades Until the Fed's out of the Way
  7. Cerulean Pharma Attracts Investors and Possible Suitor, Protalix Returns to the Spotlight
  8. Waltham-based cancer drug firm Cerulean Pharma may seek a buyer
  9. Cerulean Announces Review of Strategic Alternatives
  10. 3 Reasons Why Cerulean Pharma (CERU) is a Great Momentum Stock
  11. 5 Stocks Poised for Major Breakouts--Gold, Pharma and Tech
  12. Edited Transcript of CERU earnings conference call or presentation 3-Nov-16 8:30pm GMT
  13. Key FDA Decisions and Trial Results Expected in October
  14. Barclays Remains Positive On Cerulean Pharma Despite Failed Renal Cancer Trial
  15. 6 Companies That Destroyed Shareholders Last Week
  16. Cerulean Pharma Inc (CERU): What’s Next?
  17. Thursday’s Top Health Care Stocks Punishing Investors
  18. Cerulean Pharma (CERU) Stock Tumbles on Lead Kidney Cancer Drug Failure
  19. Cerulean (CERU) Kidney Cancer Drug Disappoints in Phase II